Skip To Main Content
Onco-Thai Inserm on Muck Rack

Onco-Thai Inserm

As seen in: EClinicalMedicine, Journal of The American Academy of Dermatology (JAAD)
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Onco-Thai

Contact Onco-Thai, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

When to stop immunotherapy for advanced melanoma: the emulated target trials

|
By AP-HP Dermato-oncology, Laurent Mortier, Onco-Thai Inserm, Mathilde Amiot
| EClinicalMedicine Verified
Keywords Advanced melanoma Duration of treatment Immunotherapy Emulated trial Evidence before this study Immune checkpoint inhibitors have demonstrated their efficacy in advanced melanoma. In trials, treatment was continued until progression, toxicity or a maximum of 2 years. Continuing treatment indefinitely predisposes patients to immune toxicities, interferes with their quality of life and represents a major economic cost.
Open in Who Shared Issue with article?

Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort

|
By Stéphane Dalle, Laurent Mortier, Perrine Rousset, Onco-Thai Inserm
| Journal of The American Academy of Dermatology (JAAD) Verified
Clinical outcomes of advanced melanoma of unknown primary (MUP) in the era of novel therapies have been scarcely studied. To investigate the efficacy and safety of systemic treatments in patients with advanced MUP compared to patients with stage-matched melanoma of known cutaneous primary (cMKP).
Open in Who Shared Issue with article?
See all 2 articles